<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02058420</url>
  </required_header>
  <id_info>
    <org_study_id>IRB L14-056</org_study_id>
    <secondary_id>American River Nutrition</secondary_id>
    <nct_id>NCT02058420</nct_id>
  </id_info>
  <brief_title>Tocotrienols and Bone Health of Postmenopausal Women</brief_title>
  <official_title>Effect of Tocotrienols on Bone Health: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Woman's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis (severe bone loss) is a bone disease with bone fragility and an increased chance&#xD;
      for bone fractures. Women are 4 times more likely to have osteoporosis than men because there&#xD;
      is no estrogen protection after menopause and women in general have lighter and thinner&#xD;
      bones. Recent studies have indicated tocotrienols (one kind of vitamin E) supplement may be&#xD;
      good for the bone health in postmenopausal women. However, no study has ever been done the&#xD;
      role of tocotrienols in bone health in postmenopausal women. Our long-term goal is to develop&#xD;
      a new strategy featuring a dietary supplement (i.e., tocotrienols) for slowing down bone loss&#xD;
      in postmenopausal women. The purpose of the study is to examine the effect of 12-week&#xD;
      tocotrienols on bone measurements in postmenopausal women. Investigators plan to recruit&#xD;
      postmenopausal women using flyers, non-solicited e-mail system, campus announcement, local&#xD;
      radio, newspapers, and TV scripts. We plan to enroll approximately 200 women to obtain 78&#xD;
      qualified women at the start of the study. After screening, qualified participants will be&#xD;
      matched by body weight and age, and then randomly assigned to no tocotrienols, low&#xD;
      tocotrienols, or high tocotrienols group. The outcome measures will be assessed at baseline,&#xD;
      after 6, and after 12 weeks. Bone-related measurements will be recorded using blood and urine&#xD;
      samples. Investigators will monitor safety of subjects after 6 and after 12 weeks. Food&#xD;
      intake, physical activity, and quality of life will be assessed at baseline and 12 weeks. All&#xD;
      data will be analyzed statistically.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum bone resorption marker</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
    <description>serum C-terminal cross-linked telopeptide of type I collagen, CTX Change from baseline CTX at 12 weeks. Investigators will also assess change from baseline CTX at 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum bone formation marker</measure>
    <time_frame>baseline, after 6 weeks, after 12 weeks</time_frame>
    <description>serum N-terminal propeptide of type I collagen, PINP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Oxidative stress marker</measure>
    <time_frame>baseline, after 6 weeks, after 12 weeks</time_frame>
    <description>8-hydroxy-2'-deoxyguanosine (8-OHdG) and urinary F2-isoprostanes (also called 8-iso-PGF2α)</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function test</measure>
    <time_frame>baseline, after 6 weeks, after 12 weeks</time_frame>
    <description>serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life Survey</measure>
    <time_frame>baseline, after 6 weeks, after 12 weeks</time_frame>
    <description>SF-36 survey (v2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum tocotrienols concentrations</measure>
    <time_frame>baseline, after 6 weeks, after 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No active dose of tocotrienols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low tocotrienols group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose of tocotrienols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High tocotrienols group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose of tocotrienol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low tocotrienols group</intervention_name>
    <description>300 mg tocotrienols daily</description>
    <arm_group_label>Low tocotrienols group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High tocotrienols group</intervention_name>
    <description>600 mg tocotrienols daily</description>
    <arm_group_label>High tocotrienols group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Postmenopausal women with no menses for 1-10 years.&#xD;
&#xD;
          2. Bone mass with bone mineral density (BMD) T-score between 0.5 and -2.5 at the spine&#xD;
             and/or hip.&#xD;
&#xD;
          3. Normal laboratory evaluation, thyroid function: TSH &gt; 0.3 and &lt; 5.0 mU/L; hepatic&#xD;
             function: bilirubin ≤ 2.0 mg/dl; SGOT (also called AST)/SGPT (also called ALT) &lt; 3x&#xD;
             upper limit of normal; renal function: serum creatinine ≤ 2.0 mg/dl; BUN less than 1.5&#xD;
             times upper limit of normal; serum calcium, phosphorus, and alkaline phosphatase:&#xD;
             within normal ranges. HbA1c &lt; 7.0%.&#xD;
&#xD;
          4. Serum 25-OH vitamin D &gt;= 20 ng/mL.&#xD;
&#xD;
          5. Age 40 and older&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. History of, or evidence for, metabolic bone disease including recent fractures (other&#xD;
             than low BMD).&#xD;
&#xD;
          2. Having received medication (calcitonin, raloxifene, or systemic glucocorticoids)&#xD;
             within 3 months before the start of the study.&#xD;
&#xD;
          3. Having bisphosphonate within 12 months before the start of the study.&#xD;
&#xD;
          4. Having hormone/hormone-like replacement therapy within 3 months before the initiation&#xD;
             of the study.&#xD;
&#xD;
          5. History of cancer except for treated superficial basal or squamous cell carcinoma of&#xD;
             the skin.&#xD;
&#xD;
          6. History or evidence of endocrine disease or malabsorption syndrome that would be a&#xD;
             contraindication to the investigation of tocotrienols' absorption.&#xD;
&#xD;
          7. Uncontrolled diabetes mellitus defined by an HbA1c of ≥ 7% in the last 3 months.&#xD;
&#xD;
          8. History of statin or other drug for cholesterol-control within 3 months before the&#xD;
             start of the study.&#xD;
&#xD;
          9. Alcohol intake greater than &quot;moderate&quot; (one drink per day) or use of nonsteroidal&#xD;
             anti-inflammatory drugs on a regular basis.&#xD;
&#xD;
         10. Cognitive impairment, depression or other medical/eating disorders, likely to move&#xD;
             during the trial, lack of transportation, distance from the study site, or unavailable&#xD;
             at sample collection times.&#xD;
&#xD;
         11. Smoking &gt; 10 cigarettes/day.&#xD;
&#xD;
         12. Unwilling to accept randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 1, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2014</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

